AstraZeneca PLC
CNBC’s Inside India newsletter: A slowing economy hasn’t dimmed India’s allure at Davos
The World Economic Forum in Davos on January 20, 2025. Fabrice Coffrini | AFP | Getty Images This report is from this week’s CNBC’s “Inside India” newsletter which brings you timely, insightful news and market commentary on the emerging powerhouse and the big businesses behind its meteoric rise. Like what you see? You can subscribe here. […]
Read More
J&J says its lung cancer drug combination keeps people alive longer
Niels Wenstedt | Getty Images Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically […]
Read More
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey. Spencer Platt | Getty Images Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. The oral drug has not yet […]
Read More
Healthy Returns: Wall Street mulls over Amgen’s weight loss drug data
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Wall Street is chewing over critical […]
Read More
Three global stocks to own in 2025, according to Barclays
The outlook for equity markets looks “decent” going into 2025, according to Barclays, as central banks cut interest rates and the global economy remains resilient. “Given limited valuation uplift for frothy parts of the market, global equities may struggle to deliver outsized risk-adjusted returns again in 2025. But they still screen favorably vs. bonds, cash […]
Read More
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
The office building of biopharmaceutical company AstraZeneca is being seen in Shanghai, China, on May 23, 2024. Nurphoto | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. AstraZeneca said it is doubling down […]
Read More
The 2 things that will drive the stock market after last week’s Trump-Fed rally
President Donald Trump looks on as his nominee for the chairman of the Federal Reserve Jerome Powell takes to the podium during a press event in the Rose Garden at the White House, November 2, 2017 in Washington, DC. Drew Angerer | Getty Images Talk about an eventful week. Normally, when the Fed cuts interest […]
Read More
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
Aykut Karahan | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Happy Friday! Buried in the election news this week was new data from drugmakers vying to enter the booming weight […]
Read More
AstraZeneca shares fall on report of potential China probe fallout
The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. Costfoto | Future Publishing | Getty Images AstraZeneca shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker’s senior executives in China could be implicated in the largest insurance fraud […]
Read More
AstraZeneca says its China operations president under investigation
The office building of biopharmaceutical company AstraZeneca is being seen in Shanghai, China, on May 23, 2024. Nurphoto | Getty Images AstraZeneca‘s China president is under investigation and is cooperating with Chinese authorities, the company said on Wednesday, sending shares down as much as 5.3%. It was not immediately clear whether the executive Leon Wang […]
Read More